127 related articles for article (PubMed ID: 35830558)
1. The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
Westhofen T; Buchner A; Kasivisvanathan V; Lennartz S; Schlenker B; Becker A; Stief CG; Kretschmer A
J Urol; 2022 Nov; 208(5):1056-1054. PubMed ID: 35830558
[TBL] [Abstract][Full Text] [Related]
2. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
[TBL] [Abstract][Full Text] [Related]
3. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
4. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.
Pompe RS; Karakiewicz PI; Tian Z; Mandel P; Steuber T; Schlomm T; Salomon G; Graefen M; Huland H; Tilki D
J Urol; 2017 Aug; 198(2):354-361. PubMed ID: 28216329
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
6. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
[TBL] [Abstract][Full Text] [Related]
7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
8. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
Xu H; Zhu Y; Dai B; Ye DW
Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
[TBL] [Abstract][Full Text] [Related]
9. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
10. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
11. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
12. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
Martini A; Gandaglia G; Karnes RJ; Zaffuto E; Bianchi M; Gontero P; Chlosta P; Gratzke C; Graefen M; Tilki D; Cucchiara V; Mirone V; Kneitz B; Sanchez Salas R; Van Der Poel H; Tombal B; Spahn M; Joniau TS; Montorsi F; Briganti A;
Eur Urol Oncol; 2019 Jul; 2(4):456-463. PubMed ID: 31277783
[TBL] [Abstract][Full Text] [Related]
13. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
14. Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence.
Knipper S; Sadat-Khonsari M; Boehm K; Mandel P; Budäus L; Steuber T; Maurer T; Heinzer H; Schwarz R; Sauter G; Tilki D; Huland H; Graefen M
Clin Genitourin Cancer; 2020 Apr; 18(2):e112-e121. PubMed ID: 31648965
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer.
Zhao HW; Li J; Cao JZ; Lin J; Wang Z; Lv JY; Wei JH; Chen ZH; Yao HH; Pan YH; Gao ZL; Luo JH; Chen W; Shi L; Fang Y
BMC Urol; 2020 Jul; 20(1):100. PubMed ID: 32677927
[TBL] [Abstract][Full Text] [Related]
16. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
17. Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer.
Ito Y; Udo K; Vertosick EA; Sjoberg DD; Vickers AJ; Al-Ahmadie HA; Chen YB; Gopalan A; Sirintrapun SJ; Tickoo SK; Scardino PT; Eastham JA; Reuter VE; Fine SW
J Urol; 2019 Mar; 201(3):535-540. PubMed ID: 30300632
[TBL] [Abstract][Full Text] [Related]
18. Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.
Kim DK; Koo KC; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
J Korean Med Sci; 2018 Nov; 33(45):e285. PubMed ID: 30402050
[TBL] [Abstract][Full Text] [Related]
19. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
20. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
